Brain ischemia occurs when the blood supply to any part of the brain is interrupted, resulting in tissue death and loss of brain function. The most common cause of brain ischemia stroke is atherosclerosis. Other conditions that may result from brain ischemia are stroke, cardiorespiratory arrest, and irreversible brain damage. The causes of brain ischemia can vary from sickle cell anemia to congenital heart defects. The symptoms of brain ischemia include loss of movement of body area, weakness, numbness, decreased vision, loss of memory, vertigo, loss of coordination and urinary incontinence. There are two kinds of brain ischemia, focal ischemia (confined to a specific region of the brain) and global ischemia (encompasses wide areas of brain tissue). The treatment of brain ischemia includes analgesics to control severe headache, anti-hypertensive medication to control high blood pressure and anti-platelet agents. The drug candidates of brain ischemia pipeline include, but are not limited to, NBS 10, NA 1 and Vepoloxamer.
Some of the companies having drugs in the pipeline for brain ischemia includes Lixte Biotechnology Holdings, Inc., NeuroNascent, Inc. and Prolong Pharmaceuticals, LLC.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.